55
Participants
Start Date
June 4, 2015
Primary Completion Date
April 9, 2018
Study Completion Date
April 9, 2018
remestemcel-L
Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Albert Einstein College of Medicine, New York
Alfred I. DuPont Hospital for Children of the Nemours Foundation, Wilmington
Virginia Commonwealth University, Richmond
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Miami Children's Research Institute, Miami
University of Mississippi Medical Center, Jackson
Children's Hospital of Michigan, Detroit
Medical College of Wisconsin, Milwaukee
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University, St Louis
Texas Transplant Institute, San Antonio
Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora
Children's Hospital Los Angeles, Los Angeles
Children's Hospital of Orange County, Orange
University of California at San Francisco, San Francisco
Oregon University, Portland
Fred Hutchinson Cancer Research, Seattle
Lead Sponsor
Quintiles, Inc.
INDUSTRY
Mesoblast, Inc.
INDUSTRY